Literature DB >> 32835366

Clinical Features of 57 Patients with Lipoid Congenital Adrenal Hyperplasia: Criteria for Nonclassic Form Revisited.

Tomohiro Ishii1,2,3, Toshihiro Tajima1,4, Kenichi Kashimada1,2,5, Tokuo Mukai1,2,6, Yusuke Tanahashi1,7, Noriyuki Katsumata1,8, Junko Kanno2,9, Takashi Hamajima2,10, Kenichi Miyako2,11, Shinobu Ida2,12, Tomonobu Hasegawa1,3.   

Abstract

CONTEXT: Lipoid congenital adrenal hyperplasia (LCAH) is caused by mutations in STAR. Classic (CLCAH) and nonclassic (NCLCAH) forms were reported as total and partial deficiencies, respectively, of adrenal and gonadal steroid hormones. The rarity of LCAH has precluded large-scale epidemiological and clinical investigations.
OBJECTIVE: To determine the epidemiological and clinical characteristics of 2 forms of LCAH.
DESIGN: A multicenter cross-sectional cohort study in Japan on December 1, 2017. PARTICIPANTS: Fifty-seven patients with LCAH (median age, 23.7 years; range, 0.0-47.5 years). MAIN OUTCOME MEASURES: Patient demographics, STAR genotype, Quigley grade, endocrinological and imaging data, treatment, and prognosis.
RESULTS: Fifty-three and 4 patients fulfilled definite and probable diagnostic criteria for LCAH, respectively. When NCLCAH was defined as either Quigley grade 1 in XY karyotype, no episode of salt losing or requirement of fludrocortisone, or onset of primary adrenal insufficiency (PAI) at 1 year or older, patients were divided into groups of 43 patients with CLCAH (75.4%), 11 with NCLCAH (19.3%), and 3 with unclassified LCAH (5.3%). All of the patients with CLCAH and 7/11 NCLCAH (63.6%) were treated with fludrocortisone. CLCAH was diagnosed at a significantly younger age than NCLCAH (median, 0.0 vs 4.0 years). STAR-Arg272Cys or -Met225Thr was identified only in NCLCAH (8/11, 72.7%).
CONCLUSIONS: We demonstrated the relative proportions and clinical and molecular characteristics of NCLCAH and CLCAH in Japan. These criteria for NCLCAH correspond to all previously published cases and our cases whose masculinization of the external genitalia, ability of mineralocorticoid production, and onset of PAI were described. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 STARzzm321990 ; Japan; classic form; lipoid congenital adrenal hyperplasia; nonclassic form; steroidogenic acute regulatory protein

Year:  2020        PMID: 32835366     DOI: 10.1210/clinem/dgaa557

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

2.  A Novel Intronic Pathogenic Variant in STAR With a Dominant Negative Mechanism Causes Attenuated Lipoid Congenital Adrenal Hyperplasia.

Authors:  Erin Finn; Kimberly Kripps; Christina Chambers; Michele Rapp; Naomi J L Meeks; Fang Xu; Wuyan Chen; Austin A Larson; Natalie J Nokoff
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

3.  Novel STAR gene variant in a patient with classic lipoid congenital adrenal hyperplasia and combined pituitary hormone deficiency.

Authors:  Moritake Higa; Akiko Zaha; Akiko Takushi; Nami Morishima; Toyofumi Majikina; Takeshi Touma; Michio Shimabukuro; Hiroaki Masuzaki; Misa Honda; Tomonobu Hasegawa
Journal:  Hum Genome Var       Date:  2021-02-03

Review 4.  Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia.

Authors:  Mattia Barbot; Pierluigi Mazzeo; Martina Lazzara; Filippo Ceccato; Carla Scaroni
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-01       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.